Key facts
- Pleno’s last known valuation is $80.6M (May 2022).
- It has raised $73.5M; the latest was Later Stage VC ($25.0M) in Dec 2024.
- Notable investors include Alexandria Venture Investments, Foresite Capital, Deerfield Management, Medical Excellence Capital, EvoNexus.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Pleno
- ·The full record, as it builds
Funding rounds
No funding rounds for Pleno are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pleno
Developer of a multi-omic instrument designed for biological target detection for clinical testing and biomedical research. The company's platform provides monitoring of minimal residual disease and early multi-cancer screening, also detects a diverse collection of analytical targets that include deoxyribonucleic acid, ribonucleic acid, and protein biomarkers with unprecedented speed and precision, and leverages advanced microfluidics to automate all aspects of sample preparation and analysis, enabling healthcare providers to get access to diverse health monitoring technologies.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2017
- Employees
- 37
- Website
- plenoinc.com/
- Ownership
- Privately Held (backing)
Pleno doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pleno shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pleno in its N-PORT filings yet. We sweep new filings monthly.